Michael Henderson
Directeur Général chez APOGEE THERAPEUTICS, INC.
Fortune : 24 M $ au 30/06/2024
Profil
Michael Henderson a fondé PellePharm, Inc. Il est directeur général de QED Therapeutics, Inc. et directeur général d'Origin Biosciences, Inc. et directeur commercial de BridgeBio Pharma, Inc. et siège au conseil d'administration de 5 autres sociétés. Dans le passé, il a occupé le poste d'associé principal chez McKinsey & Co, Inc. Le Dr Henderson a obtenu un diplôme de premier cycle à l'université de Harvard et un doctorat à l'université de Stanford.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 05/07/2024 | 594 740 ( 1,32% ) | 23 M $ | 30/06/2024 | |
| 31/01/2024 | 30 000 ( 0,80% ) | 344 550 $ | 30/06/2024 | |
SPYRE THERAPEUTICS, INC
-.--% | 14/05/2024 | 0 ( -.--% ) | - $ | 30/06/2024 |
Postes actifs de Michael Henderson
| Sociétés | Poste | Début |
|---|---|---|
| ARYA SCIENCES ACQUISITION CORP IV | Directeur/Membre du Conseil | 25/02/2021 |
| SPYRE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 22/06/2023 |
| APOGEE THERAPEUTICS, INC. | Directeur Général | 01/06/2023 |
QED Therapeutics, Inc.
 QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Directeur Général | - |
Origin Biosciences, Inc.
 Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Directeur Général | - |
Therasis, Inc.
 Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/09/2016 |
| Adrenas Therapeutics, Inc. | Directeur/Membre du Conseil | 01/07/2017 |
| Quartz Therapeutics, Inc. | Directeur/Membre du Conseil | 01/09/2016 |
TheRas, Inc.
 TheRas, Inc. Medical/Nursing ServicesHealth Services TheRas, Inc. engages in biotechnological research, which develops program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is headquartered in Palo Alto, CA. | Directeur/Membre du Conseil | 01/09/2016 |
Anciens postes connus de Michael Henderson
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | - |
Formation de Michael Henderson
| Harvard University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| SPYRE THERAPEUTICS, INC. | Health Technology |
| BRIDGEBIO PHARMA, INC. | Health Technology |
| ARYA SCIENCES ACQUISITION CORP IV | Finance |
| APOGEE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
PellePharm, Inc.
 PellePharm, Inc. BiotechnologyHealth Technology PellePharm, Inc. engages in the operation of a biotechnology company committed to targeting rare dermatologic diseases. It develops Patidegib , an investigational topical treatment designed to mitigate the tumor burden in patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs), and other potential indications. The firm also focuses on commercializing Patidegib treatment by potentially reducing invasive and painful surgeries. The company was founded by Michael Henderson, Jean Tang, Ervin Epstein, and Philip Beachy and is headquartered in San Francisco, CA. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Therasis, Inc.
Therasis, Inc. Pharmaceuticals: MajorHealth Technology Therasis, Inc. develops oncology drugs. It offers oncology therapeutics for use as single agents or in combination therapy. The firm's proprietary technology, the Therasis Filter, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers and this platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. The company was founded by Owen A. O'Connor and Riccardo Dalla-Favera in 2007 and is headquartered in New York, NY. | Health Technology |
QED Therapeutics, Inc.
QED Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017. | Health Technology |
Origin Biosciences, Inc.
Origin Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018. | Health Technology |
| Quartz Therapeutics, Inc. | |
| Adrenas Therapeutics, Inc. | |
TheRas, Inc.
TheRas, Inc. Medical/Nursing ServicesHealth Services TheRas, Inc. engages in biotechnological research, which develops program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is headquartered in Palo Alto, CA. | Health Services |
